Stay updated on Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial

Sign up to get notified when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    No significant changes to the study page content are observable between the screenshots; only minor formatting/layout differences are present. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T21:25:50.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    35 days ago
    Change Detected
    Summary
    Added a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.
    Difference
    2%
    Check dated 2025-10-06T07:53:49.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Summary
    Version update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.
    Difference
    0.0%
    Check dated 2025-09-29T04:13:14.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    The page version updated from v3.0.1 to v3.0.2. The Back to Top element was removed, with no changes to core content.
    Difference
    0.1%
    Check dated 2025-09-14T21:51:43.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The page has updated the publication date of a significant clinical trial article from May 8, 2025, to July 1, 2025, and has revised the version number from v3.0.0 to v3.0.1.
    Difference
    0.3%
    Check dated 2025-09-07T18:24:11.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has been updated to include a new facility name and location, along with a significant publication related to a clinical trial involving pembrolizumab for metastatic triple negative breast cancer. Additionally, the revision number has been updated to v3.0.0.
    Difference
    5%
    Check dated 2025-08-31T12:26:24.000Z thumbnail image

Stay in the know with updates to Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.